We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

87 hedge funds and large institutions have $94.8M invested in Enzo Biochem, Inc. in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,000% more call options, than puts

Call options by funds: $142K | Put options by funds: $2K

3% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 32

5% less funds holding

Funds holding: 9287 (-5)

6% less capital invested

Capital invested by funds: $101M → $94.8M (-$6.36M)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
87
Holders Change
-5
Holders Change %
-5.43%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
9
Increased
31
Reduced
32
Closed
13
Calls
$142K
Puts
$2K
Net Calls
+$140K
Net Calls Change
-$338K
Name Holding Trade Value Shares
Change
Change in
Stake
PCM
51
Prelude Capital Management
New York
$132K +$6.68K +1,400 +5%
PP
52
PDT Partners
New York
$130K +$27.7K +5,800 +25%
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$126K +$3.93K +825 +3%
PRC
54
Platte River Capital
Colorado
$124K -$949K -198,950 -88%
NFA
55
Nationwide Fund Advisors
Ohio
$116K
Deutsche Bank
56
Deutsche Bank
Germany
$114K +$121K +25,431 +7,660%
Neuberger Berman Group
57
Neuberger Berman Group
New York
$107K
OC
58
Oppenheimer & Co
New York
$107K +$115K +24,194 New
AIG
59
American International Group
New York
$99.9K -$3.94K -826 -4%
NCCM
60
Nine Chapters Capital Management
New Jersey
$99K -$35.8K -7,500 -25%
BA
61
BlackRock Advisors
Delaware
$98K
UBS Group
62
UBS Group
Switzerland
$98K +$105K +21,919 New
CS
63
Credit Suisse
Switzerland
$76K -$75.1K -15,747 -48%
Bank of America
64
Bank of America
North Carolina
$73K +$36.7K +7,706 +89%
CSS
65
Cubist Systematic Strategies
Connecticut
$67K -$9.04K -1,896 -11%
MCM
66
Maple Capital Management
Vermont
$62K +$66.8K +14,000 New
RCM
67
Rotella Capital Management
Washington
$61K +$8.58K +1,800 +15%
T. Rowe Price Associates
68
T. Rowe Price Associates
Maryland
$58K
GC
69
Guggenheim Capital
Illinois
$50K +$54K +11,318 New
Invesco
70
Invesco
Georgia
$49K -$24.9K -5,230 -32%
Susquehanna International Group
71
Susquehanna International Group
Pennsylvania
$46K -$15.6K -3,278 -24%
RFC
72
Russell Frank Company
Washington
$31K -$680K -142,549 -95%
TSW
73
Thompson Siegel & Walmsley
Virginia
$30K
Citigroup
74
Citigroup
New York
$27K +$23.7K +4,974 +401%
LTFS
75
Ladenburg Thalmann Financial Services
Florida
$17K

ENZ Hedge Fund Activity: Q4 2014 in Review

87 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2014, worth a combined $94.8M — down 6.3% from $101M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ENZ and 9 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $10.2M. The largest seller was EAM Investors, exiting entirely with an estimated $3.53M sold.

  • 87 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2014, down from 92 in Q3 2014.
  • Funds reported $94.8M of Enzo Biochem, Inc. stock for Q4 2014, down 6.3% quarter-over-quarter.
  • 9 funds opened new Enzo Biochem, Inc. positions in Q4 2014 and 13 closed out, a net change of -4 holders.
  • The largest Enzo Biochem, Inc. buyer in Q4 2014 was Wellington Management Group, an estimated $10.2M added.
  • The largest Enzo Biochem, Inc. seller in Q4 2014 was EAM Investors, an estimated $3.53M sold.

Based on aggregated 13F filings for Q4 2014.